Biogen Statistics

Total Valuation

Biogen has a market cap or net worth of ARS 39.72 trillion. The enterprise value is 43.12 trillion.

Market Cap	39.72T
Enterprise Value	43.12T

Important Dates

The next estimated earnings date is Thursday, April 30, 2026.

Earnings Date	Apr 30, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.82%
Shares Change (QoQ)	-0.27%
Owned by Insiders (%)	0.20%
Owned by Institutions (%)	96.02%
Float	146.28M

Valuation Ratios

The trailing PE ratio is 21.17 and the forward PE ratio is 12.20.

PE Ratio	21.17
Forward PE	12.20
PS Ratio	2.77
PB Ratio	1.50
P/TBV Ratio	10.58
P/FCF Ratio	13.34
P/OCF Ratio	12.41
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.20, with an EV/FCF ratio of 14.49.

EV / Earnings	22.98
EV / Sales	3.09
EV / EBITDA	8.20
EV / EBIT	10.82
EV / FCF	14.49

Financial Position

The company has a current ratio of 2.68, with a Debt / Equity ratio of 0.36.

Current Ratio	2.68
Quick Ratio	1.70
Debt / Equity	0.36
Debt / EBITDA	1.79
Debt / FCF	3.25
Interest Coverage	10.56

Financial Efficiency

Return on equity (ROE) is 7.39% and return on invested capital (ROIC) is 11.19%.

Return on Equity (ROE)	7.39%
Return on Assets (ROA)	6.14%
Return on Invested Capital (ROIC)	11.19%
Return on Capital Employed (ROCE)	10.82%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	1.91B
Profits Per Employee	250.20M
Employee Count	7,500
Asset Turnover	0.34
Inventory Turnover	0.90

Taxes

In the past 12 months, Biogen has paid 382.59 billion in taxes.

Income Tax	382.59B
Effective Tax Rate	16.94%

Stock Price Statistics

The stock price has increased by +64.88% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+64.88%
50-Day Moving Average	20,894.00
200-Day Moving Average	16,489.70
Relative Strength Index (RSI)	54.50
Average Volume (20 Days)	3,305

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.57

Income Statement

In the last 12 months, Biogen had revenue of ARS 14.36 trillion and earned 1.88 trillion in profits. Earnings per share was 12,757.81.

Revenue	14.36T
Gross Profit	11.33T
Operating Income	4.10T
Pretax Income	2.26T
Net Income	1.88T
EBITDA	5.23T
EBIT	4.10T
Earnings Per Share (EPS)	12,757.81

Balance Sheet

The company has 5.54 trillion in cash and 9.66 trillion in debt, giving a net cash position of -3,497.87 billion.

Cash & Cash Equivalents	5.54T
Total Debt	9.66T
Net Cash	-3,497.87B
Net Cash Per Share	n/a
Equity (Book Value)	26.50T
Book Value Per Share	180,503.54
Working Capital	8.16T

Cash Flow

In the last 12 months, operating cash flow was 3.20 trillion and capital expenditures -223.23 billion, giving a free cash flow of 2.98 trillion.

Operating Cash Flow	3.20T
Capital Expenditures	-223.23B
Free Cash Flow	2.98T
FCF Per Share	n/a

Margins

Gross margin is 78.95%, with operating and profit margins of 28.55% and 13.07%.

Gross Margin	78.95%
Operating Margin	28.55%
Pretax Margin	15.74%
Profit Margin	13.07%
EBITDA Margin	36.44%
EBIT Margin	28.55%
FCF Margin	20.73%

Dividends & Yields

Biogen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.82%
Shareholder Yield	-0.82%
Earnings Yield	4.72%
FCF Yield	7.49%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Biogen has an Altman Z-Score of 2.97 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.97
Piotroski F-Score	6